III-01 Elin Boger
Drug targeting in pulmonary sub-epithelial compartments predicted through systems pharmacology modelling
Thursday 09:50-11:20 |
III-02 Esther Encinas
Application of modelling and simulation (M&S) methods within the context of a paediatric-use marketing authorisation (PUMA) application
Thursday 09:50-11:20 |
III-03 Elvira Erhardt
Comparison of pharmacokinetic parameters estimated by the experimental R package 'nlmixr' and MONOLIX
Thursday 09:50-11:20 |
III-04 Ruben Faelens
Clinical trial optimization of efficacy studies in slowly progressive diseases
Thursday 09:50-11:20 |
III-05 Kevin Feng
Study and application of nonparametric and parametric population modeling for automatic subpopulation classification to CYP2D6 phenotype compounds and pediatric age groups
Thursday 09:50-11:20 |
III-06 Cecilia Fosser
Model based predictions of the PTG-100 pharmacodynamic responses in ulcerative colitis patients
Thursday 09:50-11:20 |
III-07 Jose Francis
Influence of nevirapine and ritonavir/lopinavir based antiretroviral therapy on Lumefantrine exposure in HIV-1 infected patients.
Thursday 09:50-11:20 |
III-08 Aline Fuchs
Minimization of a utility function for optimizing the dosing frequency of amoxicillin administration in neonates according to a fixed PK/PD index
Thursday 09:50-11:20 |
III-09 Saskia Fuhrmann
Model-based comparison of mAb clearance in pediatric populations*
Thursday 09:50-11:20 |
III-10 María García-Cremades
Mechanistic multi-scale systems pharmacokinetics model applied for the anticancer drug gemcitabine in pancreatic cancer
Thursday 09:50-11:20 |
III-11 Iain Gardner
A Whole body Physiologically based Pharmacokinetic Model for Antibody drug conjugates - model development and validation in rat
Thursday 09:50-11:20 |
III-13 Silke Gastine
Population Pharmacokinetics of Micafungin in critically ill patients - evaluation of a fixed dose regimen
Thursday 09:50-11:20 |
III-14 Francois Gaudreault
Circadian quantitative system pharmacology model to inform clinical study design and translation to human
Thursday 09:50-11:20 |
III-15 Parviz Ghahramani
Antimicrobial Drug Development Common Practices in PK-PD Model Selection and Common Misconceptions
Thursday 09:50-11:20 |
III-16 Anais Glatard
Varenicline exposure is associated with abstinence from smoking in a cohort of smokers from the general population
Thursday 09:50-11:20 |
III-17 Ignacio Gonzalez-Garcia
Comparison of FO – FOCE population parameter estimation methods in PhysPK 2.0 against NONMEM 7.3
Thursday 09:50-11:20 |
III-18 Sungwoo Goo
Population pharmacokinetics(PK)/Pharmacodynamics(PD) modeling and simulation of vancomycin in pediatric infectious patients
Thursday 09:50-11:20 |
III-19 Verena Gotta
Conceptual evaluation of urea rebound in pediatric hemodialysis patients by a physiology-based pharmacokinetic simulation study
Thursday 09:50-11:20 |
III-20 Sebastiaan Goulooze
Kernel-based visual hazard comparison (kbVHC): a simulation-free diagnostic for parametric repeated time-to-event models
Thursday 09:50-11:20 |
III-21 Silvia Grandoni
Evaluation of a minimal WB-PBPK platform supporting different routes of administration
Thursday 09:50-11:20 |
III-22 Ana-Marija Grisic
Towards understanding the loss of response to infliximab in patients with inflammatory bowel disease: A population PK modelling approach
Thursday 09:50-11:20 |
III-23 Benjamin Guiastrennec
Model-based prediction of plasma concentration and enterohepatic circulation of total bile acids in human
Thursday 09:50-11:20 |
III-24 Monia Guidi
Adequacy of open-loop Target Controlled Infusion devices during anesthesia
Thursday 09:50-11:20 |
III-25 Anubha Gupta
Power calculation methods to detect covariates effect when combining observed and simulated data.
Thursday 09:50-11:20 |
III-26 Serge Guzy
Population Pharmacokinetic of L-DOPA and its main metabolites: Use of the Phoenix based QRPEM algorithm
Thursday 09:50-11:20 |
III-27 Bengt Hamrén
Pharmacokinetic and exposure-response analyses supporting ticagrelor dosing recommendation in patients with prior myocardial infarction (PEGASUS-TIMI 54)
Thursday 09:50-11:20 |
III-28 Nina Hanke
Physiologically-based pharmacokinetic (PBPK) modeling of alfentanil as a CYP3A4 victim drug
Thursday 09:50-11:20 |
III-29 Niklas Hartung
Quantifying adaptive resistance in bacteria using well-designed dynamic time-kill curve experiments
Thursday 09:50-11:20 |
III-30 Paul Healy
Impact of metabolic polymorphism on the exposure to tramadol and its active metabolite in children
Thursday 09:50-11:20 |
III-31 Lee Heechan
A population parmacokinetic analysis of fimasartan, a novel angiotensin-receptor antagonist, in healthy subjects and patients with hypertension
Thursday 09:50-11:20 |
III-32 Eleanor Howgate
Sensitivity analysis of P-glycoprotein Ki values in dynamic DDI predictions
Thursday 09:50-11:20 |
III-33 Gailing Li
Mechanism-Based Modeling In Chronic Heptatis B
Thursday 09:50-11:20 |
III-34 Moustafa M. A. Ibrahim
Model-based diagnostics post-processing for fast automated model building; show-cased with residual error models and CWRES.
Thursday 09:50-11:20 |
III-35 Ibrahim Ince
Extension of a pregnancy physiologically-based pharmacokinetic model for renally cleared drugs to the postpartum period
Thursday 09:50-11:20 |
III-36 Itziar Irurzun-Arana
Population PD modelling of circulating biomarkers in patients with melanoma treated with interferon alpha2b
Thursday 09:50-11:20 |
III-37 Masoud Jamei
Virtual Bioequivalence Assessment of Two Tramadol Formulations using the Advanced Dissolution Absorption and Metabolism (ADAM) model via Simcyp R Package
Thursday 09:50-11:20 |
III-38 Candice Jamois
Quantification of Anti-Drug-Antibodies (ADA) Impact on Drug Exposure Using a Population PK modeling Approach
Thursday 09:50-11:20 |
III-39 Julie Janssen
Clinical trial simulations to optimize dose finding studies in paediatric oncology
Thursday 09:50-11:20 |
III-40 Jihyun Jeon
Pharmacokinetic modeling of Donepezil after transdermal administration in rat
Thursday 09:50-11:20 |
III-41 Jin Jin
Crenezumab exposure-response across Alzheimer’s Disease endpoints supports a higher dose for Phase 3
Thursday 09:50-11:20 |
III-42 Martin Johnson
Exposure response relationship for interstitial lung disease (ILD) events following osimertinib treatment
Thursday 09:50-11:20 |
III-43 Koen Jolling
CHF5993 a triple combination therapy for COPD patients: population pharmacokinetic modelling of beclometasone-17-monopropionate (B17MP) following pMDI inhalation.
Thursday 09:50-11:20 |
III-44 Siv Jonsson
Placebo and drug response assessment on Unified Parkinson’s Disease Rating Scale using longitudinal Item Response Modelling
Thursday 09:50-11:20 |
III-45 Matts Kågedal
Herceptin in HER2-positive Gastric Cancer: Evaluation of Exposure-Response with Two Dose Levels.
Thursday 09:50-11:20 |
III-46 Vangelis Karalis
On the population pharmacokinetics and the enterohepatic recirculation of inhaled formoterol in asthma patients
Thursday 09:50-11:20 |
III-47 Johannes Kast
Antibiotic Efficacy during Spaceflight: Impact of Simulated Microgravity on Killing of S. pneumoniae by Ciprofloxacin
Thursday 09:50-11:20 |
III-48 Tatiana Khariton
Human Population PK Model, Dose Selection and Target Attainment Simulations for CF-301 - a Novel Antibacterial Lysin
Thursday 09:50-11:20 |
III-49 Yu Kyong Kim
Population Pharmacokinetic Model Development for Long-Acting Intramuscular Injection of Drug X in Healthy Subjects
Thursday 09:50-11:20 |
III-50 Yun Kim
A population pharmacokinetic analysis of voriconazole according to CYP2C19 phenotype in healthy subjects
Thursday 09:50-11:20 |
III-51 Lena Klopp-Schulze
Exploring and explaining variability in tamoxifen and endoxifen pharmacokinetics in breast cancer patients: A pooled analysis
Thursday 09:50-11:20 |
III-52 Frank Kloprogge
Pharmacodynamics of vancomycin in children
Thursday 09:50-11:20 |
III-53 Ben Kluender
Pharmacokinetic and Exposure-Response Analyses for Extrapolation of Efficacy of Adalimumab in Adolescent Patients with Hidradenitis Suppurativa
Thursday 09:50-11:20 |
III-54 Franziska Isabelle Kluwe
Population pharmacokinetics of unbound voriconazole following two different routes of administration during sequence therapy
Thursday 09:50-11:20 |
III-55 Jane Knöchel
A novel measure of importance of state variables for model reduction: results for the blood coagulation network
Thursday 09:50-11:20 |
III-56 Gilbert Koch
Characterization of heart rate and sleeping patterns in pre-term neonates
Thursday 09:50-11:20 |
III-57 Yuri Kosinsky
Radiation and anti-PD-L1 treatment combinations: Immune cell responses and dose scheduling optimization using a joint experimental and systems modeling approach
Thursday 09:50-11:20 |
III-58 Pavel Kovalenko
Pharmacodynamic (PD) model of neutrophil margination to describe transient effect of sarilumab on absolute neutrophil count (ANC) in patients with rheumatoid arthritis (RA) after single-dose administration
Thursday 09:50-11:20 |
III-59 Anu Shilpa Krishnatry
Population pharmacokinetics and pharmacodynamics of GSK525762 in patients with solid tumors
Thursday 09:50-11:20 |
III-60 Anders Kristoffersson
A Novel Mechanism-Based Pharmacokinetic-Pharmacodynamic Model Describing Ceftazidime-Avibactam (CAZ-AVI) Efficacy Against β-lactamase-Producing Klebsiella pneumoniae and Pseudomonas aeruginosa Isolates
Thursday 09:50-11:20 |
III-61 Fabiola La Gamba
A Bayesian PK/PD model for synergy; a case study
Thursday 09:50-11:20 |
III-62
Population pharmacokinetics of Rimeporide: a sodium-hydrogen exchanger (NHE-1) inhibitor for patients with Duchenne Muscular Dystrophy (DMD)
Thursday 09:50-11:20 |
III-63 Silvia Maria Lavezzi
Modelling of rituximab clearance reduction due to ibrutinib co-administration
Thursday 09:50-11:20 |
III-64 Jacob Leander
Pharmacodynamic modeling of uric acid turnover and the effect of Verinurad (RDEA3170), a novel selective uric acid reabsorption inhibitor for the treatment of gout and asymptomatic hyperuricemia
Thursday 09:50-11:20 |
III-65 Jong Bong Lee
In silico modelling of chylomicron association to predict lymphatic absorption of small molecules
Thursday 09:50-11:20 |
III-66 Donghwan Lee
Population pharmacokinetic analysis of meropenem in Korean patients with acute infections
Thursday 09:50-11:20 |
III-67 Jennifer Leohr
A Semi-Physiologic Model of Postprandial Triglyceride Response following Anti-Obesity Therapy
Thursday 09:50-11:20 |
III-68 Sarah Lezzar
Population pharmacokinetics and pharmacodynamics analysis of hydroxyurea, in adult patients with sickle cell anemia (SCA), and evaluation of disease markers
Thursday 09:50-11:20 |
